Merrimack Pharmaceuticals Inc. Announces Expansion of Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer
6/28/2012 9:29:49 AM
CAMBRIDGE, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that it has expanded the global Phase 3 study of MM-398 versus an infusional regimen of 5-fluorouracil (5-FU) and leucovorin (folinic acid) (LV) in patients with metastatic pancreatic cancer where a gemcitabine-containing regimen has failed. The study has been expanded to include an additional arm which combines MM-398 with 5-FU and LV. The Phase 3 study, called NAPOLI-1 (NAnoliPOsomaL Irinotecan), is scheduled to begin enrollment on the amended protocol in July.